EUROPEAN ACADEMY OF PAEDIATRICS

Their core work

The European Academy of Paediatrics (EAP) is a pan-European professional association representing practising paediatricians and paediatric subspecialists across Europe. Their core value in research consortia is twofold: they bring authoritative clinical expertise in child and adolescent health, and they serve as a gateway to a broad network of practising physicians who can contribute to studies, trials, and implementation efforts. In H2020, they have contributed to medical device regulatory science — providing the paediatric clinical perspective on evidence standards for high-risk devices — and to public health research on childhood vaccination, particularly addressing why underserved communities have lower MMR and HPV uptake. They are not a research institute; they are a credentialed professional body whose value lies in clinical authority, European-wide reach, and the ability to translate research into clinical practice recommendations.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2021, so there is no true temporal progression to trace — the "early vs. recent" keyword split reflects two parallel tracks running simultaneously rather than a shift over years. The first track (CORE-MD) is regulatory and evidence-based: medical devices, clinical investigation standards, device registries. The second track (RIVER-EU) is public health and equity-focused: vaccine uptake, community engagement, health system access for marginalised groups. Taken together, these two parallel engagements suggest EAP is positioning itself as a clinical standards authority on two fronts — what goes into children's bodies (devices and medicines) and how health systems reach those children in the first place.

EAP appears to be broadening from a purely clinical/regulatory advisory role toward active public health research on equity and access — a direction consistent with growing EU-level concern about vaccination hesitancy and health inequalities in paediatric populations.

How they like to work

EAP consistently joins projects as a participant rather than leading them — a pattern typical of professional medical associations that provide expert input and network access rather than managing research operations. Their two projects both involve large international consortia (36 unique partners across 17 countries combined), which reflects their value as a connector: they bring in the broader European clinical community rather than a narrow specialist team. Working with EAP means gaining access to a professional network of paediatricians across Europe, but project management and scientific coordination will sit with other consortium members.

EAP has collaborated with 36 unique partners across 17 countries through just two projects, indicating they typically participate in large, geographically diverse consortia — consistent with their pan-European mandate. Their network is European in scope with no apparent single-country bias.

What sets them apart

EAP is one of very few H2020 participants that brings the formal voice of an entire medical specialty — paediatrics — rather than the perspective of a single institution or research group. For a consortium needing clinical legitimacy, access to practising physicians across multiple EU countries, or the ability to disseminate findings directly into clinical practice, EAP is a rare asset. Their dual engagement in regulatory science and vaccine equity also makes them unusual: they can credibly speak to both the technical standards of medical interventions and the human and social dimensions of whether those interventions actually reach children.

Highlights from their portfolio

• RIVER-EU
  The largest EAP project by funding (EUR 139,750) and duration (2021–2026), targeting one of Europe's most politically sensitive public health challenges — childhood vaccine hesitancy in underserved communities — using participatory action research methods.
• CORE-MD
  Addresses the regulatory gap in evidence standards for high-risk medical devices, with EAP providing the paediatric clinical perspective on device registries and trial methodologies in areas like cardiology and diabetes.